CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $251.97M, lower than 95% of all stocks globally
- PositionOperating margin is 45.1%, higher than 95% of its Biotechnology peers (median -42.4%)
- Interpretations11 currently firing — 1 · 10
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.57%Below 5Y avg (3.84%)
Annual Rate
TWD 2.00Paid annual
Payout Ratio
160.3%High
Payback Period
27.7 yr
Last Ex-Dividend
Aug 17, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
High Dividend Payout With FCF And Equity Ratio
→dividend payout intensity
fcf positive 3y
ratio balance equity
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.02BTWD251.97M · vs all stocks (USD)
Trailing P/E
14.92xvs Biotechnology peers
Revenue (TTM)
1.03BTWD32.22M · vs all stocks (USD)
Profit Margin
52.56%vs Biotechnology peers
Beta
0.1370xvs all stocks
52-Week Change
-15.45%vs all stocks
Market Capitalization
8.02BTWD251.97M · vs all stocks (USD)
Enterprise Value
2.95BTWD92.86M · vs all stocks (USD)
Trailing P/E
14.92xvs Biotechnology peers
Forward P/E
20.22xvs Biotechnology peers
PEG Ratio
0.0221xvs Biotechnology peers
Price to Sales (TTM)
7.82xvs Biotechnology peers
Price to Book (MRQ)
1.63xvs Biotechnology peers
Enterprise to Revenue
2.88xvs Biotechnology peers
Enterprise to EBITDA
6.07xvs Biotechnology peers
Gross Margin
92.66%vs Biotechnology peers
Profit Margin
52.56%vs Biotechnology peers
Operating Margin
45.13%vs Biotechnology peers
Return on Assets (TTM)
5.44%vs Biotechnology peers
Return on Equity (TTM)
11.26%vs Biotechnology peers
Revenue (TTM)
1.03BTWD32.22M · vs all stocks (USD)
Revenue per Share (TTM)
7.13TWDUpdated Sep 21, 2026Quarterly Revenue Growth
31.10%vs Biotechnology peers
Gross Profit (TTM)
962.23MTWD30.24M · vs all stocks (USD)
EBITDA (TTM)
657.72MTWD20.67M · vs all stocks (USD)
Net Income (TTM)
538.80MTWD16.93M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
653.60%vs Biotechnology peers
Operating Cash Flow (TTM)
540.65MTWD16.99M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-275.12MTWD-8.65M · vs all stocks (USD)
Trailing Annual Dividend Rate
2.00TWDUpdated Sep 21, 2026Trailing Annual Dividend Yield
3.57%vs all stocks
5-Year Average Dividend Yield
3.84%vs all stocks
Payout Ratio
160.34%vs Biotechnology peers
Revenue
911.42MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
51.85MTWDFY2025 · Dec 31, 2025Gross Profit
859.56MTWDFY2025 · Dec 31, 2025Operating Income
425.48MTWD13.37M · vs all stocks (USD)
Pre-tax Income
509.29MTWDFY2025 · Dec 31, 2025Income Tax Expense
121.65MTWDFY2025 · Dec 31, 2025Net Income
387.64MTWDFY2025 · Dec 31, 2025EBIT
509.43MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
519.50MTWDFY2025 · Dec 31, 2025Research & Development
299.72MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
134.37MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
96.10MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
139.00KTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
1.98BTWDFY2025 · Dec 31, 2025Free Cash Flow
1.98BTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.58BTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
509.29MTWDFY2025 · Dec 31, 2025Stock-based Compensation
403.00KTWDFY2025 · Dec 31, 2025Other Non-cash Items
-95.96MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.58BTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.84MTWDFY2025 · Dec 31, 2025Capital Expenditures
-280.00KTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00TWDFY2025 · Dec 31, 2025Purchase of Investments
-3.79BTWDFY2025 · Dec 31, 2025Sale of Investments
3.53BTWDFY2025 · Dec 31, 2025Other Investing Activity
-194.00KTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
-266.65MTWDFY2025 · Dec 31, 2025Common Dividends Paid
-861.92MTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
-861.92MTWDFY2025 · Dec 31, 2025Shares Outstanding
143.68MSharesUpdated Sep 21, 2026Float Shares
93.45MSharesUpdated Sep 21, 2026% Held by Insiders
21.60%vs all stocks
% Held by Institutions
19.75%vs all stocks
Total Cash (MRQ)
5.07BTWD159.40M · vs all stocks (USD)
Total Cash per Share (MRQ)
35.30TWDUpdated Sep 21, 2026Total Debt (MRQ)
37.78MTWD1.19M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0077xvs Biotechnology peers
Current Ratio (MRQ)
11.21xvs Biotechnology peers
Book Value per Share (MRQ)
34.17TWDUpdated Sep 21, 2026Total Assets
5.15BTWD161.78M · vs all stocks (USD)
Total Current Assets
5.08BTWDFY2025 · Dec 31, 2025Total Liabilities
221.59MTWDFY2025 · Dec 31, 2025Total Non-current Assets
62.67MTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
34.45MTWDFY2025 · Dec 31, 2025Total Current Liabilities
187.15MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.58BTWDFY2025 · Dec 31, 2025Other Short-term Investments
3.13BTWDFY2025 · Dec 31, 2025Accounts Receivable
83.89MTWDFY2025 · Dec 31, 2025Inventory
39.87MTWDFY2025 · Dec 31, 2025Accounts Payable
35.58MTWDFY2025 · Dec 31, 2025Short-term Debt
8.66MTWDFY2025 · Dec 31, 2025Other Current Liabilities
1.76MTWDFY2025 · Dec 31, 2025Long-term Debt
33.46MTWDFY2025 · Dec 31, 2025Common Stock (Book)
1.46BTWDFY2025 · Dec 31, 2025Retained Earnings
1.48BTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
4.93BTWD154.82M · vs all stocks (USD)
Treasury Stock
133.41MTWDFY2025 · Dec 31, 202552-Week Low
53.00TWDUpdated Sep 21, 202652-Week High
74.40TWDUpdated Sep 21, 202652-Week Change
-15.45%vs all stocks
Beta
0.1370xvs all stocks
50-Day MA
60.97TWDUpdated Sep 21, 2026200-Day MA
61.89TWDUpdated Sep 21, 2026Avg 10-Day Volume
286.65KSharesUpdated Sep 21, 2026Avg 30-Day Volume
279.60KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
3.74TWDUpdated Sep 21, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Drawdown With FCF And Cash Backing
Well below its peak, with three years of positive free cash flow behind it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 45.1%, higher than 95% of its Biotechnology peers (median -42.4%)Significant
Operating margin: 0.45Industry median: -0.42Industry P95: 0.30Peers compared: 258
Profit margin is 52.6%, higher than 95% of its Biotechnology peers (median -57.5%)Significant
Profit margin: 0.53Industry median: -0.58Industry P95: 0.37Peers compared: 258
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $251.97M, lower than 95% of all stocks globallySignificant
Market cap (USD): 251,972,965.754Global P5: 283,534,814
Revenue is $32.22M, lower than 95% of all stocks globallySignificant
Revenue (USD): 32,216,547.379Global P5: 35,820,060.775
Companies that share the same coordination system — how they create, deliver, or capture value.
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Acimmune SA
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Colgate-Palmolive (India) Ltd.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedCash-Flow Ratios ElevatedDrawdown With FCF And Cash BackingClose Below 40W SMA With ProfitabilityIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsCash Backing With OCF Coverage And Cash Near Total Debt
Transportadora de Gas del Norte S.A.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Dividend Payout With FCF And Equity RatioFCF Ratios ElevatedCash-Flow Ratios ElevatedDrawdown With FCF And Cash BackingClose Below 40W SMA With ProfitabilityThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsCash Backing With OCF Coverage And Cash Near Total Debt
Chongqing Road & Bridge Co., Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsHigh Dividend Payout With FCF And Equity RatioCash-Flow Ratios ElevatedDrawdown With FCF And Cash BackingClose Below 40W SMA With ProfitabilityThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsLow-Leverage Liquidity ConfigurationCash Backing With OCF Coverage And Cash Near Total Debt